- ISIN
- US46116X1019
- CUSIP
- 46116X101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 7, 2014
Highlights
- Total Revenue (TTM)
- $680.64M
- Gross Profit (TTM)
- $623.67M
- EBITDA (TTM)
- -$116.21M
- Target Price
- $98.50
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ITCI Performance Chart
Loading charts...
Returns By Period
Intra-Cellular Therapies, Inc.
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
ITCI Monthly Returns History
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 52.16% | 0.88% | 2.90% | -0.04% | 57.89% | ||||||||
| 2024 | -5.98% | 3.24% | -0.46% | 3.77% | -6.36% | 1.86% | 14.94% | -6.91% | -0.15% | 15.83% | 1.06% | -2.49% | 16.62% |
| 2023 | -9.45% | 2.32% | 10.44% | 14.77% | -4.46% | 6.64% | -2.34% | -10.22% | -6.18% | -4.47% | 23.33% | 16.70% | 35.34% |
| 2022 | -9.27% | 16.82% | 10.29% | -17.29% | 13.42% | -0.56% | -5.19% | -7.13% | -7.42% | -1.85% | 18.72% | -2.40% | 1.11% |
| 2021 | 1.10% | 10.20% | -4.23% | 1.47% | 14.46% | 3.58% | -15.90% | -3.29% | 12.29% | 15.53% | -6.01% | 29.30% | 64.59% |
Benchmark Metrics
Intra-Cellular Therapies, Inc. has an annualized alpha of 46.66%, beta of 1.11, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since January 08, 2014.
- This stock captured 148.64% of S&P 500 Index gains and 101.39% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 46.66%
- Beta
- 1.11
- R²
- 0.04
- Upside Capture
- 148.64%
- Downside Capture
- 101.39%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Intra-Cellular Therapies, Inc. (ITCI) and compare them to S&P 500 Index.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Intra-Cellular Therapies, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Intra-Cellular Therapies, Inc. was 87.64%, occurring on Oct 1, 2019. Recovery took 619 trading sessions.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2019 bear market2019 | -87.64%Oct 2019 | 3y 10mo | 2y 5mo | 6y 3moNov 2015 - Mar 2022 |
2015 bear market2015 | -36.81%Sep 2015 | 10d | 2mo | 2mo 10dSep 2015 - Nov 2015 |
2014 bear market2014 | -35.41%Sep 2014 | 6mo 13d | 3mo 23d | 10mo 6dMar 2014 - Jan 2015 |
Bear market2022 | -34.95%Sep 2022 | 5mo 22d | 7mo 16d | 1y 1moApr 2022 - May 2023 |
2023 bear market2023 | -30.21%Oct 2023 | 5mo 22d | 1mo 22d | 7mo 14dMay 2023 - Dec 2023 |
Drawdown Indicators
| ITCI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | — | -56.78% | — |
Max Drawdown (1Y)Largest decline over 1 year | — | -9.10% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | — | -0.74% | — |
Average DrawdownAverage peak-to-trough decline | — | -10.72% | — |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 1.97% | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Intra-Cellular Therapies, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Intra-Cellular Therapies, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ITCI
Add Intra-Cellular Therapies, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ITCI